Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Chief Legal Officer & Corp Sec | March 06, 2026 | March 10, 2026 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | SENIOR VP AND GENERAL COUNSEL | February 07, 2019 | February 11, 2019 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Legal Officer | August 17, 2022 | August 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,999 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 2,090 · Balance 176,089 Row 2 · 2026-03-06 · Sale · Disposed 2,090 · Balance 173,999 F1: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2035-01-06 | Direct | 71,048 |
Reported balance
After 2026-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-06 · Exercise / conversion · Disposed 2,090 · Balance 71,048 F2: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
F2: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.
GENOCEA BIOSCIENCES, INC.
Report date February 07, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2029-02-07 | Direct | 200,000 |
Reported balance
After 2019-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-07 · Grant · Acquired 200,000 · Balance 200,000 F1: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest). |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest).
X4 Pharmaceuticals, Inc
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,155 |
Reported balance
After 2022-08-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-08-17 · Sale · Disposed 8,334 · Balance 145,155 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.155 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Represents unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.155 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2026 Filed Mar 10, 2026 21:45 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,090 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001628280-26-016645 · wk-form4_1773193523.xml · derivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,048 Underlying: Common Stock · 2,090 shares Expires 2035-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:45 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,090 | $3.26 | $6,813.40 |
DisclosureSEC source: 0001628280-26-016645 · wk-form4_1773193523.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,999 F1 · kind: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:45 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 2,090 | $1.85 | $3,866.50 |
DisclosureSEC source: 0001628280-26-016645 · wk-form4_1773193523.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:42 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,406 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001628280-26-014365 · wk-form4_1772592146.xml · derivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,138 Underlying: Common Stock · 9,406 shares Expires 2035-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:42 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 9,406 | $3.01 | $28,311.12 |
DisclosureSEC source: 0001628280-26-014365 · wk-form4_1772592146.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,999 F1 · kind: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:42 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 9,406 | $1.85 | $17,401.10 |
DisclosureSEC source: 0001628280-26-014365 · wk-form4_1772592146.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,671 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · derivative · entry 6 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,544 Underlying: Common Stock · 2,671 shares Expires 2035-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,671 | $3.00 | $8,017.27 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · nonDerivative · entry 4 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,999 F1 · kind: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 2,671 | $1.85 | $4,941.35 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · nonDerivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,085 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · derivative · entry 5 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,215 Underlying: Common Stock · 15,085 shares Expires 2035-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the employee stock option vest in 48 equal monthly installments starting on the date the option was granted, such that the option will be fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 15,085 | $3.00 | $45,262.54 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,999 F1 · kind: The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.0000 to $3.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 19:50 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 15,085 | $1.85 | $27,907.25 |
DisclosureSEC source: 0001628280-26-003948 · wk-form4_1769647801.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 18:12 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 5,633 | $1.90 | $10,717.91 |
DisclosureSEC source: 0001628280-26-003349 · wk-form4_1769209972.xml · nonDerivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,999 F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8800 to $1.9400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 18:12 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,054 | $1.84 | $1,939.36 |
DisclosureSEC source: 0001628280-26-003349 · wk-form4_1769209972.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,632 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:12 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,247 | $1.81 | $4,063.25 |
DisclosureSEC source: 0001628280-26-003349 · wk-form4_1769209972.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,686 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 18:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 148,700 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001628280-26-002960 · wk-form4_1769038296.xml · derivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,700 Underlying: Common Stock · 148,700 shares Expires 2036-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 18:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 99,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002960 · wk-form4_1769038296.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,933 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 18:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 8,548 | $1.71 | $14,658.11 |
DisclosureSEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 4 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,800 F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 18:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 5,200 | $1.76 | $9,169.16 |
DisclosureSEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,348 F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 18:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 30,092 | $1.82 | $54,866.74 |
DisclosureSEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,548 F3 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 18:51 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 6,819 | $1.82 | $12,379.21 |
DisclosureSEC source: 0001628280-26-001896 · wk-form4_1768261867.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,640 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 21:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 10,070 | $1.99 | $20,035.27 |
DisclosureSEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 5 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,459 F4 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F7 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0250. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 21:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,700 | $1.99 | $3,378.92 |
DisclosureSEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 4 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,529 F5 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F6 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 3,801 | $1.97 | $7,476.57 |
DisclosureSEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,229 F4 · shares: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 7,097 | $1.97 | $13,961.22 |
DisclosureSEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,030 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,000 | $1.96 | $7,838.00 |
DisclosureSEC source: 0001628280-26-001262 · wk-form4_1767839440.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,127 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9200 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 17:16 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 3,418 | $1.59 | $5,434.62 |
DisclosureSEC source: 0001576885-25-000033 · wk-form4_1737670600.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,127 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 19:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 100,300 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001576885-25-000015 · wk-form4_1736297850.xml · derivative · entry 3 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,300 Underlying: Common Stock · 100,300 shares Expires 2035-01-06 F4 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 19:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 66,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000015 · wk-form4_1736297850.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,545 F3 · shares: Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 19:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 11,122 | $1.84 | $20,505.63 |
DisclosureSEC source: 0001576885-25-000015 · wk-form4_1736297850.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,745 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7750 to $1.9300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2024 Filed Jan 19, 2024 19:06 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 8,933 | $3.48 | $31,048.43 |
DisclosureSEC source: 0001576885-24-000027 · wk-form4_1705709183.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,867 F1 · shares: Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.4000 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 137,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001576885-24-000012 · wk-form4_1704403314.xml · derivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 91,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-24-000012 · wk-form4_1704403314.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:21 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 120,800 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-23-003735 · doc4.xml · derivative · entry 2 Meisner Derek M · CIK 0001752461 · Chief Legal Office & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,800 Underlying: Common Stock · 120,800 shares Expires 2033-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 16:21 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 26,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003735 · doc4.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Office & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 16:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $6.08 | $0.00 |
DisclosureSEC source: 0001209191-22-049019 · doc4.xml · derivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Office & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-09-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on September 6, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 13:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 8,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-023326 · wf-form4_166092887277332.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,155 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.155 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 16:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018042 · wf-form4_165636047780166.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,489 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 16:21 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-017433 · wf-form4_165549724891007.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,655 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.01 to $1.13, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 16:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004493 · wf-form4_164616887905021.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,821 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 15,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-002509 · wf-form4_164487371477082.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,821 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.53 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 16:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 8,332 | $5.10 | $42,493.20 |
DisclosureSEC source: 0001628280-21-017332 · wf-form4_162940476414343.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,730 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $4.98 to $5.35, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,166 | $7.00 | $29,162.00 |
DisclosureSEC source: 0001628280-21-012932 · wf-form4_162465138910056.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,062 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.86 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012932 · wf-form4_162465138910056.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,228 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,166 | $7.84 | $32,661.44 |
DisclosureSEC source: 0001628280-21-012478 · wf-form4_162396436372680.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,728 F2 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.72 to $8.19, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Represents unvested restricted stock units. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 17:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012478 · wf-form4_162396436372680.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,894 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 15, 2021. One third of the shares will vest on June 15, 2022, and one third of the shares will vest on June 15, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:54 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 47,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-005658 · wf-form4_161670563770115.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,394 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Represents unvested restricted stock units. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 08:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 8,334 | $8.05 | $67,088.70 |
DisclosureSEC source: 0001628280-20-013419 · wf-form4_159974106828347.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.57 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 16,666 shares represent unvested restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012840 · wf-form4_159779585056386.xml · nonDerivative · entry 2 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F3 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 17, 2020. One third of the shares will vest on August 17, 2021, and one third of the shares will vest on August 17, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F4 · balance_after: Of the shares of common stock reported, 16,666 shares represent unvested restricted stock units. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012840 · wf-form4_159779585056386.xml · nonDerivative · entry 1 Meisner Derek M · CIK 0001752461 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 14, 2020. One third of the shares will vest on August 14, 2021, and one third of the shares will vest on August 14, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 8,333 shares represent unvested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.